07:30 - 9:00 a.m.	CEO Breakfast
09:30 - 11:30 a.m.	Navigating the Global Market
11:30 - 01:30 p.m.	The Impact Strategic Research has in the US Market
1:30 - 2:45 p.m.	The Asia Pacific Biotechnology Capital
3:15 - 5:00 p.m.	Accessing Capital - Australian and New Zealand Co-Investment with US Partners

Introducer:	• Dr. Una Ryan, CEO of AVANT Immunotherapeutics, Inc
Presenters:	• Dr. Stewart Washer CEO Phylogica • Peter Chapman Cook, CEO & Managing Director, Biota Holdings Ltd • Dr. Sandra Webb, SVP Phosphagenics Limited • Dr. Julian Chick, CEO Avexa Limited • Dr Roland Scollay, CEO of Metabolic Pharmaceuticals • David Clarke, CEO Neuren Pharmaceuticals Limited
The CEO Breakfast provides US investors and executives the opportunity to hear Australasia's leading biopharmaceutical CEO's present on:
	• the latest developments in their organizations
	• their US business focus • how they are seeking to or have successfully raised capital in the US

A selection of Australasia's most successful biopharmaceutical CEO's will provide 10 minute
presentations followed by a Q & A session to be moderated by a US biotechnology expert.


Malcolm J. Binks, Chairman American Australian Association

Introducer:	• Michael Levy, VP Alliance Management, Bristol-Myers Squibb
Moderator:	• Dr. Bruce Pratt, VP Science Development, Genzyme Corporation
Presenters:	• Dr. Greg Collier, CEO, ChemGenex Pharmaceuticals • Dr. Shreefal Mehta, VP Business and Corporate Development, Cytopia Inc. • Dr. Kenneth P. Taylor, President & CEO Advanced Ocular Systems Ltd. • Dr. William Wardell, President, Wardell Associates International, LLC

Leading industry players in the Australasian biotechnology industry are making the move to go global
by setting up US offices and collaborating or merging with US ventures.

Case studies will focus on a selection of successful Australasian biotechnology corporations where the company is currently working with US partner(s) or in the process of setting up relationships with US corporations.

This session is geared towards those interested in hearing about novel and innovative biotechnology
discoveries, whether the attendee is a scientist or an executive involved in business development, new technology evaluation or licensing, or from a venture capital or investment company.

Case studies will highlight exciting new technologies and business models that advance the drug
discovery and development process.

Keynote speaker: Dr. Hugo Stephenson, President of Quintiles Strategic Research Services
" The Impact Strategic Research has in the US Market: What Global Companies Should Know"

Introducer:	• Dr Anna Lavelle, CEO AusBiotech Ltd
Moderator:	• James E. Foley, VP, Business Development Bristol-Myers Squibb
Panelists:	• David Darling, CEO of Pacific Edge Biotechnology • Stephen Carter, Managing Director & CEO of Solbec Pharmaceuticals • Will Charles, General Manager Auckland Uni Services

This panel will consider the opportunities Australasia offers as well as the value for global biotechnology and pharmaceutical companies, both as a lucrative consumer market and a source of innovation.

Examples will be provided of successful partnerships between Australasian and US companies which have provided revenue streams for Australasian companies and new sources of new technology in the United States.

Introducer & Moderator: Professor Josh Lerner, Harvard Business School
Panelists:	Dr. Ed Mascioli, Executive Partner, MPM Capital Campbell Murray, Novartis Bio Venture Fund Tom Salemi, Editor, The Venture Capital Analyst, Dow Jones & Co. Josh Funder, GBS Ventures Al Sokol, Edwards Angell Palmer & Dodge Dr. John Holaday, Montgomery Pacific

Financing options are broadening, as the profile of a biotechnology investor changes: corporations,
individuals and private equity groups are all investing in new or expanding biotechnology ventures.

Australian and New Zealand biotechnology ventures are discovering financing options with US investors that have an Australasian appetite and can collaborate with a local backer. The majority of these are still with venture capital funds with international or Australian interests.

This panel is designed to discuss examples of US investment into Australian and New Zealand ventures and why they have been successful. It will also explore the model for successful international venture capital investment in the future.

Featuring a selection of fine Western Australian wines including wines from the famed Margaret River region